Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Hypoglycaemia is the limiting factor in the glycaemic management of diabetes. Iatrogenic hypoglycaemia is typically the result of the interplay of insulin excess and compromised glucose counterregulation in Type I (insulin-dependent) diabetes mellitus. Insulin concentrations do not decrease and glucagon and epinephrine concentrations do not increase normally as glucose concentrations decrease. The concept of hypoglycaemia-associated autonomic failure (HAAF) in Type I diabetes posits that recent antecedent iatrogenic hypoglycaemia causes both defective glucose counterregulation (by reducing the epinephrine response in the setting of an absent glucagon response) and hypoglycaemia unawareness (by reducing the autonomic and the resulting neurogenic symptom responses). Perhaps the most compelling support for HAAF is the finding that as little as 2 to 3 weeks of scrupulous avoidance of hypoglycaemia reverses hypoglycaemia unawareness and improves the reduced epinephrine component of defective glucose counterregulation in most affected patients. The mediator and mechanism of HAAF are not known but are under active investigation. The glucagon response to hypoglycaemia is also reduced in patients approaching the insulin deficient end of the spectrum of Type II (non-insulin-dependent) diabetes mellitus, and glycaemic thresholds for autonomic (including epinephrine) and symptomatic responses to hypoglycaemia are shifted to lower plasma glucose concentrations after hypoglycaemia in Type II diabetes. Thus, patients with advanced Type II diabetes are also at risk for HAAF. While it is possible to minimise the risk of hypoglycaemia by reducing risks -- including a 2 to 3 week period of scrupulous avoidance of hypoglycaemia in patients with hypoglycaemia unawareness -- methods that provide glucose-regulated insulin replacement or secretion are needed to eliminate hypoglycaemia and maintain euglycaemia over a lifetime of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because of steady improvements in the glycemic management of diabetes, it is possible both to improve glycemic control and to minimize the risk of hypoglycemia in many patients (12, 16, 84 -86).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoglycemia in diabetes is fundamentally the result of treatments that raise insulin levels and thus lower plasma glucose concentrations (12,16,84,85).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those treatments include insulin or insulin secretagogues such as a sulfonylurea or a nonsulfonylurea insulin secretagogue (e.g.nateglinide or repaglinide).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In type 1 diabetes, deficiency of the secretory response of glucagon to hypoglycemia is an early acquired abnormality of counterregulation.The catecholamine response compensates for several years but declines with time (1).”
From Hypoglycemia in Type 2 Diabetes (2005) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Treatment-induced hypoglycemia is the limiting factor in the glycemic management of diabetes (12,16,84).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Plum, F. (1960) · Archives of Neurology · doi:10.1001/archneur.1960.03840090124020 · Cited by 10,364
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 2×
“Enough insulin, or any effective drug, to lower plasma glucose concentrations to or below the normal range would eliminate the symptoms of hyperglycaemia, prevent the acute hyperglycaemic complications (ketoacidosis, hyperosmolar syndrome), almost assuredly prevent the long-term microvascular complications [1, 2] and…”
BackgroundKhaw, K.-T. (2001) · BMJ · doi:10.1136/bmj.322.7277.15 · Cited by 1,017
Gold, A. E., Macleod, K. M., & Frier, B. M. (1994) · Diabetes Care · doi:10.2337/diacare.17.7.697 · Cited by 810
Gerich, J. E., Langlois, M., Noacco, C., Karam, J. H., & Forsham, P. H. (1973) · Science · doi:10.1126/science.182.4108.171 · Cited by 688 · cited 1×
“Finally, we and others have begun to study the mechanisms of the normal glucagon response to hypoglycaemia with the aim of gaining insight into the mechanism of the absence of the glucagon response in Type I diabetes [22], a critical component of defective glucose counterregulation and HAAF.”
BackgroundMitrakou, A., Ryan, C., Veneman, T., Mokan, M., Jenssen, T., Kiss, I., Durrant, J., Cryer, P., & Gerich, J. (1991) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1991.260.1.e67 · Cited by 558 · cited 2×
“0 mmol/l (54 mg/dl) respectively) are reproducible in healthy subjects [13, 14, 15], they shift to higher plasma glucose concentrations in poorly controlled diabetes [16, 17] and to lower plasma glucose concentrations following episodes of hypoglycaemia [18, 19, 20, 21].”
BackgroundSelf-citationHeller, S. R., & Cryer, P. E. (1991) · Diabetes · doi:10.2337/diab.40.2.223 · Cited by 531
Self-citation&NA; (1994) · Survey of Anesthesiology · doi:10.1097/00132586-199406000-00052 · Cited by 487
Dagogo-Jack, S. E., Craft, S., & Cryer, P. E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116302 · Cited by 471
Self-citation
Cited by
Items 401–500 of 793
Farhy, L. S., & McCall, A. L. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01455.x · Cited by 19
Ekhlaspour, L., Tabatabai, I., & Buckingham, B. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819851790 · Cited by 17
Linagliptin as add-on therapy to insulin for patients with type 2 diabetes
Hocher, B., von Websky, K., & Reichetzeder, C. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s40035 · Cited by 17
Latta, S., Alhosaini, M., Al-Solaiman, Y., Zena, M., Khasawneh, F. A., Eranki, V., Khilwani, A., & Iroegbu, N. A. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181d1d847 · Cited by 17
“updated.(9,17) Recent trials have raised concerns about the benefit of intensive glycemic control.”
BackgroundMunshi, M. N., Gill, J., Chao, J., Nikonova, E., & Patel, M. (2017) · Endocrine Practice · doi:10.4158/ep171922.or · Cited by 17
McDonnell, M. E. (2007) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/01.hcr.0000281762.29287.a6 · Cited by 17
Kahsay, H., & Fenta, T. G. (2025) · PLoS ONE · doi:10.1371/journal.pone.0317653 · Cited by 21
“Severe hypo-glycemia, another frequent diabetic emergency, is recognized as a significant barrier to insulin therapy and is associated with higher mortality rates [30, 31].”
Hermanns, N., Kulzer, B., Gulde, C., Eberle, H., Pradler, E., Patzelt-Bath, A., & Haak, T. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2008.0078 · Cited by 16
Bailey, T. S., Willard, J., Klaff, L. J., Stone, J. Y., Melgaard, A. E., & Tehranchi, R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14475 · Cited by 16
“Recurrent hypoglycaemia and fear of hypoglycaemia remain some of the greatest barriers to achieving optimal glycaemic control in patients with diabetes, especially patients treated with insulin.(11,12) Reflecting the importance of rapidly increasing plasma glucose to regain consciousness in patients with severe hypogl…”
BackgroundAccess to emergency room for hypoglycaemia in people with diabetes
Salutini, E., Bianchi, C., Santini, M., Dardano, A., Daniele, G., Penno, G., Miccoli, R., & Prato, S. D. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2667 · Cited by 18
“Hypoglycaemia is one of the main obstacles [7,8] and a major burden of pharmacologic therapy of diabetes [9] exposing individuals to excess risk of morbidity [10] and mortality [11] and aggravating the cost of treatment [12].”
BackgroundThe Diabetes Treatment Trap: Hypoglycemia
Fowler, M. J. (2011) · Clinical Diabetes · doi:10.2337/diaclin.29.1.36 · Cited by 19
Investigation on Carbohydrate Counting Method in Type 1 Diabetic Patients
Son, O., Efe, B., Son, N., Akalın, A., & Kebapçı, N. (2014) · BioMed Research International · doi:10.1155/2014/176564 · Cited by 24
“If not hindered by hypoglycemia, the HbA1c levels of all diabetic patients would be normal throughout life [10, 20–24].”
Takahashi, R., Ishihara, H., Tamura, A., Yamaguchi, S., Yamada, T., Takei, D., Katagiri, H., Endou, H., & Oka, Y. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00131.2005 · Cited by 18
“This unresponsiveness to hypoglycemia makes precise glycemic management difficult (8), although strict control is known to be essential for preventing diabetic complications (38).”
BackgroundCharacteristics influencing expected cognitive performance during hypoglycaemia in type 2 diabetes
Petersen, J. Z., Nilsson, M. S. D., Rungby, J., & Miskowiak, K. W. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.104431 · Cited by 17
Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes
Hedrington, M. S., & Davis, S. N. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1009893 · Cited by 16
“For example, hypoglycemia increases morbidity and mortality and worsens quality of life [4-6].”
BackgroundPrevalence and Clinical Pattern of Acute and Chronic Complications in African Diabetic Patients
Jasper, U. S. (2014) · Journal of Advances in Medicine and Medical Research · doi:10.9734/bjmmr/2014/9384 · Cited by 16
“Hypoglycemia is the leading limiting factor in the glycemic management of type 1 and insulin-treated type 2 diabetes [14] and may be an obstacle to the use of insulin [15].”
BackgroundViswanathan, M., Joshi, S., & Bhansali, A. K. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.102986 · Cited by 19
“[7,9]”
InfluentialWang, J., Lee, I., Lee, W., Lin, S.-D., Su, S., Tu, S., Tseng, Y., Lin, S., & Sheu, W. H. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.12.010 · Cited by 17
“Hypoglycemia is an important limiting factor for improving glycemic control in patients with diabetes [39,40], and may be associated with adverse outcomes, including cardiovascular and arrhythmic death [20,21].”
Backgroundvan Meijel, L. A., Rooijackers, H. M. M., Tack, C. J., & de Galan, B. E. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00087 · Cited by 17
The Role of Glucagon in Glycemic Variability in Type 1 Diabetes: A Narrative Review
Guo, K., Tian, Q., Yang, L., & Zhou, Z. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s343514 · Cited by 20
“account for 4% of all-cause mortality in patients with T1DM.(84) The early study suggested that the glucagon response to hypoglycemia was lost as early as the first month after diagnosis of T1DM,(85) which was consistent”
BackgroundKobuke, K., Yoneda, M., Nakanishi, S., Ohno, H., Maeda, S., & Egusa, G. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12373 · Cited by 16
Concerns about hypoglycaemia and late complications in patients with insulin-treated diabetes
Banck-Petersen, P., Larsen, T., Pedersen‐Bjergaard, U., Bie-Olsen, L. G., Høi-Hansen, T., & Thorsteinsson, B. (2007) · European Diabetes Nursing · doi:10.1002/edn.91 · Cited by 17
Schnell, O., Erbach, M., & Wintergerst, E. S. (2013) · Journal of Diabetes Science and Technology · doi:10.1177/193229681300700413 · Cited by 16
Vivian, E. (2007) · The Consultant Pharmacist · doi:10.4140/tcp.n.2007.320 · Cited by 20
Fowler, M. J. (2008) · Clinical Diabetes · doi:10.2337/diaclin.26.4.170 · Cited by 22
Management of Type 1 Diabetes in Children and Adolescents
Jain, V. (2013) · The Indian Journal of Pediatrics · doi:10.1007/s12098-013-1196-3 · Cited by 18
Paediatric diabetes: achieving practical, effective insulin therapy in type 1 and type 2 diabetes
Danne, T., & BECKER, D. J. (2007) · Acta Paediatrica · doi:10.1111/j.1651-2227.2007.00494.x · Cited by 17
“Risk of hypoglycaemia, especially at night, is the most feared adverse event among persons with diabetes, their families and medical staff in relation to insulin treatment (49).”
BackgroundHoffman, E. G., D’Souza, N. C., Liggins, R. T., & Riddell, M. C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1295639 · Cited by 13
“Treatment-induced hypoglycemia is a pervasive clinical complication of intensive treatment with insulin analogues (T1D and T2D) and/or secretagogues (T2D) (Cryer, 2002).”
BackgroundInfluentialRamotowska, A., & Szypowska, A. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2477 · Cited by 17
“Fear of hypoglycaemia negatively influences insulin dosing and good metabolic control [18,19].”
BackgroundLeiter, L. A., Shestakova, M. V., Trubitsyna, N. P., Piletič, M., & Satman, İ. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.11.001 · Cited by 15
[Hypoglycemia in the elderly with diabetes mellitus].
Fematt, F. M. Á., & Montaña‐Álvarez, M. (2010) · PubMed · Cited by 16
Chantzaras, A. E., & Yfantopoulos, J. (2022) · Value in Health Regional Issues · doi:10.1016/j.vhri.2021.10.005 · Cited by 16
Minimizing Hypoglycemia in the Wake of a Tight Glycemic Control Protocol in Hospitalized Patients
Selig, P. M., Popek, V., & Peebles, K. M. (2010) · Journal of Nursing Care Quality · doi:10.1097/ncq.0b013e3181d373e9 · Cited by 16
El Páncreas Artificial: Control Automático de Infusión de Insulina en Diabetes Mellitus Tipo 1
Bondía, J., Vehí, J., Palerm, C. C., & Herrero, P. (2010) · Revista Iberoamericana de Automática e Informática Industrial RIAI · doi:10.1016/s1697-7912(10)70021-2 · Cited by 27
“Es precisamente la hipoglucemia el principal temor de los pacientes, debido a las consecuencias que una hipoglucemia severa puede tener, como por ejemplo el coma diabético (Cryer, 2002).”
BackgroundArtificial Pancreas Coupled Vital Signs Monitoring for Improved Patient Safety
Khan, Z. H., Khan, Z. H., & Khan, Z. H. (2012) · Arabian Journal for Science and Engineering · doi:10.1007/s13369-012-0456-2 · Cited by 15
Impact of therapeutic advances on hypoglycaemia in type 2 diabetes
Boyle, P. J., & Zrebiec, J. F. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.795 · Cited by 14
“The UK Hypoglycaemia Study group recently reported that severe hypoglycaemia is always less frequent in T2DM than in T1DM [21].”
BackgroundInfluentialSchouwenberg, B. J., Veldman, B. A. J., Spiering, W., Coenen, M. J. H., Franke, B., Tack, C. J., de Galan, B. E., & Smits, P. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f70481 · Cited by 17
Clarke, A., & Dain, M. (2006) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.5.677 · Cited by 14
“For example, if the pen delivers unexpectedly high doses of insulin, the patient is at increased risk of hypoglycaemia [19].”
BackgroundPedersen‐Bjergaard, U., Thomsen, C. E., Høgenhaven, H., Smed, A., Kjær, T. W., Holst, J. J., Dela, F., Hilsted, L., Frandsen, E., Pramming, S., et al. (2008) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2008.001 · Cited by 14
“Introduction Hypoglycaemia is the dominant side effect to insulin therapy in type 1 diabetes and represents a major barrier to achievement of optimal glycaemic control in many patients.(1) While some episodes are recognised and corrected by the patients many hypoglycaemic episodes remain unrecognised due to impaired a…”
BackgroundAmino acids and the changing face of the α-cell
Hamilton, A., Eliasson, L., & Knudsen, J. G. (2023) · Peptides · doi:10.1016/j.peptides.2023.171039 · Cited by 17
“conjunction with impaired insulin signalling to drive blood glucose levels up, while hypoglycaemia is the main barrier for effective treatment of diabetes with insulin, with the loss of the glucagon response a significant factor in its development [80].”
BackgroundAcreman, S., Ma, J., Denwood, G., Gao, R., Tarasov, A. I., Rorsman, P., & Zhang, Q. (2024) · iScience · doi:10.1016/j.isci.2024.109665 · Cited by 17
Donnelly, R., Carr, S. V., & Harper, R. (2015) · Practical Diabetes · doi:10.1002/pdi.1966 · Cited by 14
Huelgas, R. G., Peralta, F. G., Fernández, L. C., Galve, E., Casanueva, F. F., Puig‐Domingo, M., Bravo, J. J. M., Orozco‐Beltrán, D., Muñoz, J. E., Torre, E. L. M., et al. (2015) · Revista Clínica Española · doi:10.1016/j.rce.2015.07.003 · Cited by 21
Schnell, O., Alawi, H., Battelino, T., Ceriello, A., Diem, P., Felton, A.-M., Grzeszczak, W., Harno, K., Kempler, P., Satman, İ., et al. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600323 · Cited by 14
Åhrén, B., Foley, J. E., Dejager, S., Akacha, M., Shao, Q., Heimann, G., Dworak, M., & Schweizer, A. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0082-y · Cited by 13
Avoiding hypoglycaemia: a new target of care for elderly diabetic patients
Wong, C. (2015) · Hong Kong Medical Journal · doi:10.12809/hkmj144494 · Cited by 17
The kinetics of glucagon action on the liver during insulin-induced hypoglycemia
Pedersen, C., Kraft, G., Edgerton, D. S., Scott, M. F., Farmer, B., Smith, M. S., LaNeve, D. C., Williams, P. E., Moore, L. M., & Cherrington, A. D. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00466.2019 · Cited by 15
Farhy, L. S., & McCall, A. L. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400608 · Cited by 13
“[Equation (4)], or, alternatively, one of the existing C-peptide models (e.”
BackgroundMethodInfluentialZhang, Y., Xie, Y., Meng, D.-D., Zhang, H., Chen, H., & Liu, E. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-37 · Cited by 14
“This increases the risk for hypoglycemia, especially interprandial and nocturnal hypoglycaemia, thus hindering the achievement of good metabolic control [16-18].”
BackgroundTsujimoto, T., Yamamoto‐Honda, R., Kajio, H., Kishimoto, M., Noto, H., Hachiya, R., Kimura, A., Kakei, M., & Noda, M. (2015) · Medicine · doi:10.1097/md.0000000000001629 · Cited by 13
“In addition to distinct pathophysiologies and background complications, this difference may be partly attributed to the fact that T1D patients typically experience more frequent hypoglycemic episodes, which blunts the counterregulatory response due to hypoglycemia-associated autonomic failure.(16,17) Incidences of sev…”
BackgroundWieringa, T. H., de Wit, M., Twisk, J. W. R., & Snoek, F. J. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000548 · Cited by 13
Kalra, S., Deepak, M., Narang, P., Singh, V., Uvaraj, M. G., & Agrawal, N. K. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0237 · Cited by 13
Insulin therapy in elderly patients with type 2 diabetes: the role of insulin glargine
Janka, H. U. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00843.x · Cited by 14
Insulin-like growth factor-1 is a negative modulator of glucagon secretion
Mancuso, E., Mannino, G. C., Fatta, C. D., Fuoco, A., Spiga, R., Andreozzi, F., & Sesti, G. (2017) · Oncotarget · doi:10.18632/oncotarget.18514 · Cited by 12
“Glucagon is the major hyperglycaemic hormone of the body counteracting insulin effects when blood glucose falls to dangerously low levels [1].”
Backgroundde Galan, B. E., Rietjens, S. J., Tack, C. J., van der Werf, S. P., Sweep, C. G. J. (., W. M. Lenders, J., & Smits, P. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030407 · Cited by 12
Dual‐hormone treatment with insulin and glucagon in patients with type 1 diabetes
Reiband, H. K., Schmidt, S., Ranjan, A. G., Holst, J. J., Madsbad, S., & Nørgaard, K. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2632 · Cited by 14
“most limiting factor in achieving optimal glycaemic control [3].”
BackgroundRegulation of α‐cell glucagon secretion: The role of second messengers
Acreman, S., & Zhang, Q. (2022) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2021.06.001 · Cited by 14
Klonoff, D. C., Bergenstal, R. M., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A., Welsh, J. B., & Lee, S. W. (2013) · Journal of Diabetes Science and Technology · doi:10.1177/193229681300700424 · Cited by 12
van Beers, C. A. J., Kleijer, S. J., Serné, E. H., Geelhoed-Duijvestijn, P. H. L. M., Snoek, F. J., Kramer, M. H. H., & Diamant, M. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0040-3 · Cited by 14
“Hence, it remains unclear whether T1DM patients with IAH benefit from conventional RTCGM in real-life.”
BackgroundInfluentialQuiroz, G., Flores‐Gutiérrez, C., & Femat, R. (2011) · Optimal Control Applications and Methods · doi:10.1002/oca.989 · Cited by 14
“One of the effects of hormone adrenaline releasing is to promote the hepatic glucose production necessary to avoid long-term hypoglycemia episodes [29].”
BackgroundPedersen, C., Bouman, S. D., Porsgaard, T., ROSENKILDE, M. M., & Roed, N. K. (2018) · Physiological Reports · doi:10.14814/phy2.13657 · Cited by 12
“Thus, the fear of hypoglycemia is a major limiting factor in the glycemic control of diabetes (Cryer 2002).”
BackgroundFactors associated with withdrawal from insulin pump therapy: A large‐population‐based study
Merzon, E., Grossman, J., Vinker, S., Merhasin, I., Levit, S., & Golan‐Cohen, A. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3288 · Cited by 11
“However, preventing hypoglycemia is essential, especially with the use of insulin replacement therapy.(2) Insulin replacement therapy, which is mandatory in type 1 diabetes (T1DM), can also be prescribed to patients with type 2 diabetes (T2DM).”
BackgroundChapter 21 Pancreatic Network Control of Glucagon Secretion and Counterregulation
Farhy, L. S., & McCall, A. L. (2009) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(09)67021-x · Cited by 14
“N IH -PA Author M anuscript N IH -PA Author M anuscript barrier to safe treatment of diabetes (Cryer and Gerich, 1983 and Gerich, 1988) since unopposed hypoglycemia can cause coma, seizures, or even death (Cryer, 1999 and Cryer, 2002).”
BackgroundDAILEY, G. E. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00840.x · Cited by 17
Schreiber, S. A., & Russmann, A. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x242827 · Cited by 13
Camacho, R. C., Lacy, D. B., James, F. D., Donahue, E. P., & Wasserman, D. H. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00247.2005 · Cited by 12
“patients striving to maintain tight glycemic control (10).”
BackgroundFreathy, R. M., Lonnen, K., Steele, A. M., Minton, J. A. L., Frayling, T. M., Hattersley, A. T., & MacLeod, K. M. (2006) · The Review of Diabetic Studies · doi:10.1900/rds.2006.3.76 · Cited by 15
“It may be possible to reduce this by selecting type 2 patients at higher risk of hypoglycemia: over time, and with diminishing endogenous insulin production and glucose counter-regulation, the risk in type 2 diabetes approaches that of type 1 [1, 10, 33].”
BackgroundRevisiting hypoglycemia in diabetes
Gehlaut, R. R., & Shubrook, J. H. (2013) · Osteopathic Family Physician · doi:10.1016/j.osfp.2013.08.002 · Cited by 11
Sodium, Glucose and Dysregulated Glucagon Secretion: The Potential of Sodium Glucose Transporters
Armour, S. L., Frueh, A., & Knudsen, J. G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.837664 · Cited by 13
“This is part of the intra-islet communication hypothesis, suggesting that the dynamic crosstalk of high hormone levels found within the islet is the foundation of adequate secretion and regulation of insulin and glucagon (Banarer et al., 2002; Cryer, 2002; Hope et al., 2004; Meier et al., 2006).”
BackgroundMyers, L. A., Swanson, K. M., Glasgow, A. E., & McCoy, R. G. (2022) · Diabetes Care · doi:10.2337/dc21-1811 · Cited by 16
Pilemann-Lyberg, S., Thorsteinsson, B., Nørgaard, K., Zander, M., Vestergaard, H., & Røder, M. E. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.09.006 · Cited by 12
Johannesen, J., Svensson, J., Bergholdt, R., Eising, S., Gramstrup, H. M., Frandsen, E., Dick-Nielsen, J., Hansen, L., Pociot, F., Mortensen, H. B., et al. (2010) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2010.00660.x · Cited by 12
“A major limiting factor in obtaining optimal blood glucose levels in T1DM children and adolescents is the risk and fear of severe hypoglycemic events in which the patient is unconscious with or without convulsions (2).”
BackgroundAldasouqi, S. A., Sheikh, A., Klosterman, P., Kniestedt, S., Schubert, L. A., Danker, R., & Hershey, D. S. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.01.2629 · Cited by 11
Is glycemic variability important to assessing antidiabetes therapies?
Kovatchev, B. P. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0005-z · Cited by 12
“Consequently, hypoglycemia has been identified as the primary barrier to optimal diabetes management [ 12 ].”
BackgroundMorales, C., de Luis, D. A., de Arellano, A. R., Ferrario, M. G., & Lizán, L. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0143-x · Cited by 13
Hypoglycaemia in the over 75s: Understanding the predisposing factors in type 2 diabetes (T2DM)
Heald, A. H., Anderson, S. G., Cortés, G., Cholokova, V., Narajos, M., Khan, A. R., Donnahey, G., & Livingston, M. A. (2017) · Primary care diabetes · doi:10.1016/j.pcd.2017.08.002 · Cited by 12
Huang, W. Q., Guo, J. H., Yuan, C., Cui, Y. G., Diao, F., Yu, M., Liu, J. Y., Ruan, Y. C., & Chan, H. C. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00835 · Cited by 11
“Its dysregulation is considered to underlie insulin deficiency, resulting in glucose metabolic disorders, such as diabetes, hypoglycemia (Cryer, 2002; Unger and Cherrington, 2012).”
BackgroundDissanayake, H. A., Keerthisena, G. S. P., Gamage, K. K. K., Liyanage, J. H., Ihalagama, I. R. H. S., Wijetunga, W. M. U. A., Tillekaratne, T. A. D., Katulanda, G. W., & Katulanda, P. (2018) · BMC Endocrine Disorders · doi:10.1186/s12902-018-0264-0 · Cited by 12
Hypoglycaemia: ACE high or low?
Higgins, K. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00013.x · Cited by 11
Larsen, T., Banck-Petersen, P., Due-Andersen, R., Høi-Hansen, T., Pedersen‐Bjergaard, U., & Thorsteinsson, B. (2006) · European Diabetes Nursing · doi:10.1002/edn.61 · Cited by 15
Experiences with a group intervention for adolescents with type 1 diabetes and their parents
Løding, R., Wold, J., & Skavhaug, Å. (2008) · European Diabetes Nursing · doi:10.1002/edn.96 · Cited by 19
Efficacy and Safety of Insulin Detemir
Raskin, P. (2007) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(07)80005-3 · Cited by 14
Control of Glycogen Content in Retina: Allosteric Regulation of Glycogen Synthase
Osorio-Paz, I., Sánchez‐Chávez, G., & Salceda, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030822 · Cited by 11
“The slow recovery of glycogen content in the retina from insulin-treated diabetic rats most likely represent a result of the chronic liver and muscle alterations of glucose disposal reported in type 1 diabetes [27], [28], [29].”
BackgroundMikeladze, M., Hedrington, M. S., Joy, N. G., Tate, D. B., Younk, L. M., Davis, I., & Davis, S. N. (2016) · Diabetes · doi:10.2337/db16-0406 · Cited by 11
“Hypoglycemia remains a major obstacle for obtaining good metabolic control in clinical practice and is associated with severe adverse events in individuals with either type 1 or type 2 diabetes (1,2).”
Backgroundvan Beers, C. A. J., Caris, M. G., DeVries, J. H., & Serné, E. H. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.09.005 · Cited by 11
“In patients with type 1 diabetes (T1D), hypoglycemia is the main limiting factor in achieving satisfactory glucose control.(1) In the DCCT, a quadratic relationship between HbA1c and the frequency of severe hypoglycemia was seen, with the risk of severe hypoglycemia clearly increasing as HbA1c decreased.”
BackgroundKawaguchi, Y., Sawa, J., Hamai, C., Nishimura, Y., & Kumeda, Y. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13038 · Cited by 10
Seufert, J., Brath, H., Pscherer, S., Borck, A., Bramlage, P., & Siegmund, T. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12211 · Cited by 9
“Hypoglycaemia has been described as an ‘insulin reaction’ as early as 1927 soon after the discovery of insulin [21] and remains the most critical factor in achieving good glycaemic control in patients with type 2 diabetes [3,22].”
BackgroundTechnology to Reduce Hypoglycemia
Yeoh, E. C. K., & Choudhary, P. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815574547 · Cited by 12
Lalic, N. M., Russel-Szymczyk, M., Culic, M., Tikkanen, C. K., & Chubb, B. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0426-0 · Cited by 13
“Hypoglycaemia and the fear of hypoglycaemia act as barriers to timely initiation and intensification of insulin and remain the major limiting factors for achieving target levels of glucose control in insulin-treated patients with diabetes [53, 54].”
BackgroundWang, J., Lo, S., Yeh, Y., Hwu, C., Huang, C., Hsieh, C., & Sheu, W. H. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14410 · Cited by 12
Yunir, E., Nugraha, A. R. A., Rosana, M., Kurniawan, J., Iswati, E., Sarumpaet, A., Tarigan, T. J. E., & Tahapary, D. L. (2023) · Scientific Reports · doi:10.1038/s41598-023-43459-2 · Cited by 18
Marelli, G., Avanzini, F., Iacuitti, G., Planca, E., Frigerio, I., Busi, G., Carlino, L., Cortesi, L., Roncaglioni, M. C., & Riva, E. (2015) · Journal of Diabetes Research · doi:10.1155/2015/173956 · Cited by 17
“However, one of the major obstacles is the fear that too tight control may cause hypoglycemia [24].”
BackgroundThe dead in bed syndrome revisited: a review of the evidence
Weston, P. J. (2012) · Diabetes Management · doi:10.2217/dmt.12.2 · Cited by 14
“46 Cryer PE. Death during intensive glycemic therapy of diabetes: mechanisms and implications. Am. J. Med. 124, 993–996 (2011).”
BackgroundMathur, S., Boparai, J., Mediwala, S. N., Garcia, J. M., Cunningham, G. R., Marcelli, M., & Vasudevan, M. M. (2014) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709614526992 · Cited by 10
Sawka, A. M., Boulos, P., Talib, A. S., Gafni, A., Thabane, L., Παπαϊωάννου, Α., Booth, G. L., & Gerstein, H. C. (2007) · Canadian Journal of Diabetes · doi:10.1016/s1499-2671(07)13010-0 · Cited by 13
Hypoglycemia in Type 2 Diabetes—Consequences and Risk Assessment
Lingvay, I. (2011) · US Endocrinology · doi:10.17925/use.2011.07.02.95 · Cited by 13
Gingras, V., Smaoui, M. R., Cameli, C., Messier, V., Ladouceur, M., Legault, L., & RABASA-LHORET, R. P. R. (2018) · Scientific Reports · doi:10.1038/s41598-018-20785-4 · Cited by 10
Impact of Insulin Degludec in Type 2 Diabetes: Real-World Data on Effectiveness and Safety
Ponzani, P., Berra, C., Lelio, A. D., Sindaco, P., Loreto, C. D., Reggiani, F., Lucisano, G., & Rossi, M. C. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0511-4 · Cited by 12
“These findings suggest that IDeg represents an advance in diabetes therapy owing to the positive impact on hypoglycemia and fear of hypoglycemia, recognized as main barriers to the achievement of glucose targets and patient quality of life [9, 10].”
BackgroundHypoglycaemia with Pioglitazone: Analysis of data from the Prescription-Event Monitoring (PEM) study
Vlckova, V., Cornelius, V., Kasliwal, R., Buggy, Y., Wilfon, L., & Shakir, S. (2008) · Drug Safety · doi:10.2165/00002018-200831100-00042 · Cited by 10
“As tight glucose control may increase frequency of hypoglycaemia, the fear of this acute complication represents limiting factor in diabetic management [3].”
BackgroundPramlintide Reduces the Risks Associated with Glucose Variability in Type 1 Diabetes
Kovatchev, B. P., Crean, J., & McCall, A. L. (2008) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2007.0295 · Cited by 11
Metadata
- Authors
- Cryer, P.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Cryer, P.
- Venue
- Diabetologia
- Published
- 2002-06
- Volume
- 45
- Issue
- 7
- Pages
- 937-948
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2124282046
- Semantic Scholar
- ebdcc733bdd208ee1005932d38511abefb8034d6
- Cited by
- 794
- References
- 58
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 11 · 2023: 15 · 2022: 16 · 2021: 22 · 2020: 18 · 2019: 24 · 2018: 39 · 2017: 49 · 2016: 32 · 2015: 60 · 2014: 65 · 2013: 66 · 2012: 53
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p60dk020579-35)
- National Institute of Diabetes and Digestive and Kidney Diseases (R37DK027085, P60-DK20579, R37-DK27085, T32 DK07120, T32DK007120)
- National Center for Research Resources (M01-RR00036, M01RR000036)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
- Keywords
- hypoglycemia, hypoglycemia unawareness, glucose counterregulation, insulin excess, epinephrine response, glucagon response, type 1 diabetes, type 2 diabetes, glycemic control
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Epinephrine, Glucagon, Humans, Hypoglycemia, Insulin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.